Microribonucleic Acid-15a-5p Alters Adriamycin Resistance in Breast Cancer Cells by Targeting Cell Division Cycle-Associated Protein 4

References

• DeSantis CE, Ma J, Gaudet MM, et al. Breast cancer statistics, 2019. CA Cancer J Clin. 2019;69(6):438–451. doi:10.3322/caac.2158331577379
   PubMed Web of Science ®Google Scholar
• Acunzo M, Romano G, Wernicke D, Croce CM. MicroRNA and cancer–a brief overview. Adv Biol Regul. 2015;57:1–9.25294678
   PubMedGoogle Scholar
• Croset M, Pantano F, Kan CWS, et al. miRNA-30 family members inhibit breast cancer invasion, osteomimicry, and bone destruction by directly targeting multiple bone metastasis-associated genes. Cancer Res. 2018;78(18):5259–5273. doi:10.1158/0008-5472.CAN-17-305830042152
   PubMed Web of Science ®Google Scholar
• Hong BS, Ryu HS, Kim N, et al. Tumor suppressor miRNA-204-5p regulates growth, metastasis, and immune microenvironment remodeling in breast cancer. Cancer Res. 2019;79(7):1520–1534.30737233
   PubMed Web of Science ®Google Scholar
• Long X, Shi Y, Ye P, Guo J, Zhou Q, Tang Y. MicroRNA-99a suppresses breast cancer progression by targeting FGFR3. Front Oncol. 2019;9:1473. doi:10.3389/fonc.2019.0147332038996
   PubMed Web of Science ®Google Scholar
• Crigna AT, Samec M, Koklesova L, et al. Cell-free nucleic acid patterns in disease prediction and monitoring-hype or hope? EPMA J. 2020;11(4):1–25. doi:10.1007/s13167-020-00226-x32140182
   PubMed Web of Science ®Google Scholar
• Shen H, Wang D, Li L, et al. MiR-222 promotes drug-resistance of breast cancer cells to Adriamycin via modulation of PTEN/Akt/FOXO1 pathway. Gene. 2017;596:110–118. doi:10.1016/j.gene.2016.10.01627746366
   PubMed Web of Science ®Google Scholar
• Li D, Wang X, Yang M, Kan Q, Duan Z. miR3609 sensitizes breast cancer cells to Adriamycin by blocking the programmed death-ligand 1 immune checkpoint. Exp Cell Res. 2019;380(1):20–28. doi:10.1016/j.yexcr.2019.03.02530904483
   PubMed Web of Science ®Google Scholar
• Zhang W, Jiang H, Chen Y, Ren F. Resveratrol chemosensitizes Adriamycin-resistant breast cancer cells by modulating miR-122-5p. J Cell Biochem. 2019;120(9):16283–16292. doi:10.1002/jcb.2891031155753
   PubMed Web of Science ®Google Scholar
• Utaijaratrasmi P, Vaeteewoottacharn K, Tsunematsu T, et al. The microRNA-15a-PAI-2 axis in cholangiocarcinoma-associated fibroblasts promotes migration of cancer cells. Mol Cancer. 2018;17(1):10. doi:10.1186/s12943-018-0760-x29347950
   PubMed Web of Science ®Google Scholar
• Shi L, Jackstadt R, Siemens H, Li H, Kirchner T, Hermeking H. p53-induced miR-15a/16-1 and AP4 form a double-negative feedback loop to regulate epithelial-mesenchymal transition and metastasis in colorectal cancer. Cancer Res. 2014;74(2):532–542. doi:10.1158/0008-5472.CAN-13-220324285725
   PubMed Web of Science ®Google Scholar
• Bandi N, Vassella E. miR-34a and miR-15a/16 are co-regulated in non-small cell lung cancer and control cell cycle progression in a synergistic and Rb-dependent manner. Mol Cancer. 2011;10:55. doi:10.1186/1476-4598-10-5521575235
   PubMed Web of Science ®Google Scholar
• Chu J, Zhu Y, Liu Y, et al. E2F7 overexpression leads to tamoxifen resistance in breast cancer cells by competing with E2F1 at miR-15a/16 promoter. Oncotarget. 2015;6(31):31944–31957. doi:10.18632/oncotarget.512826397135
   PubMedGoogle Scholar
• Fesler A, Liu H, Ju J. Modified miR-15a has therapeutic potential for improving treatment of advanced stage colorectal cancer through inhibition of BCL2, BMI1, YAP1 and DCLK1. Oncotarget. 2018;9(2):2367–2383.29416778
   PubMedGoogle Scholar
• Cheong JK, Gunaratnam L, Zang ZJ, et al. TRIP-Br2 promotes oncogenesis in nude mice and is frequently overexpressed in multiple human tumors. J Transl Med. 2009;7:8. doi:10.1186/1479-5876-7-819152710
   PubMed Web of Science ®Google Scholar
• Tang DJ, Hu L, Xie D, et al. Oncogenic transformation by SEI-1 is associated with chromosomal instability. Cancer Res. 2005;65(15):6504–6508. doi:10.1158/0008-5472.CAN-05-035116061626
   PubMed Web of Science ®Google Scholar
• Tategu M, Nakagawa H, Hayashi R, Yoshida K. Transcriptional co-factor CDCA4 participates in the regulation of JUN oncogene expression. Biochimie. 2008;90(10):1515–1522. doi:10.1016/j.biochi.2008.05.01418572021
   PubMed Web of Science ®Google Scholar
• Hayashi R, Goto Y, Ikeda R, Yokoyama KK, Yoshida K. CDCA4 is an E2F transcription factor family-induced nuclear factor that regulates E2F-dependent transcriptional activation and cell proliferation. J Biol Chem. 2006;281(47):35633–35648. doi:10.1074/jbc.M60380020016984923
   PubMed Web of Science ®Google Scholar
• Pang S, Xu Y, Chen J, Li G, Huang J, Wu X. Knockdown of cell division cycle-associated protein 4 expression inhibits proliferation of triple negative breast cancer MDA-MB-231 cells in vitro and in vivo. Oncol Lett. 2019;17(5):4393–4400.30944632
   PubMed Web of Science ®Google Scholar
• Xu Y, Wu X, Li F, Huang D, Zhu W. CDCA4, a downstream gene of the Nrf2 signaling pathway, regulates cell proliferation and apoptosis in the MCF7/ADM human breast cancer cell line. Mol Med Rep. 2018;17(1):1507–1512.29257222
   PubMed Web of Science ®Google Scholar
• Alderman C, Sehlaoui A, Xiao Z, Yang Y. MicroRNA-15a inhibits the growth and invasiveness of malignant melanoma and directly targets on CDCA4 gene. Tumour Biol. 2016;37(10):13941–13950. doi:10.1007/s13277-016-5271-z27492455
   PubMedGoogle Scholar
• Pan J, Miao D, Chen L. Germacrone reverses Adriamycin resistance in human chronic myelogenous leukemia K562/ADM cells by suppressing MDR1 gene/P-glycoprotein expression. Chem Biol Interact. 2018;288:32–37. doi:10.1016/j.cbi.2018.04.01229655913
   PubMed Web of Science ®Google Scholar
• Stastny I, Zubor P, Kajo K, Kubatka P, Golubnitschaja O, Dankova Z. Aberrantly methylated cfDNA in body fluids as a promising diagnostic tool for early detection of breast cancer. Clin Breast Cancer. 2020;20(6):e711–e22. doi:10.1016/j.clbc.2020.05.00932792225
   PubMed Web of Science ®Google Scholar
• Qian S, Golubnitschaja O, Zhan X. Chronic inflammation: key player and biomarker-set to predict and prevent cancer development and progression based on individualized patient profiles. EPMA J. 2019;10(4):365–381. doi:10.1007/s13167-019-00194-x31832112
   PubMed Web of Science ®Google Scholar
• Wu ZH, Tao ZH, Zhang J, Li T, Hu XC. MiRNA-21 induces epithelial to mesenchymal transition and gemcitabine resistance via the PTEN/AKT pathway in breast cancer. Tumour Biol J Int Soc Oncodevelopmental Biol Med. 2015;37(6):7245–7254. doi:10.1007/s13277-015-4604-7
   PubMedGoogle Scholar
• Zhu J, Zou Z, Nie P, et al. Downregulation of microRNA-27b-3p enhances tamoxifen resistance in breast cancer by increasing NR5A2 and CREB1 expression. Cell Death Dis. 2016;7(11):e2454. doi:10.1038/cddis.2016.36127809310
   PubMed Web of Science ®Google Scholar
• Kovalchuk O, Filkowski J, Meservy J, et al. Involvement of microRNA-451 in resistance of the MCF-7 breast cancer cells to chemotherapeutic drug doxorubicin. Mol Cancer Ther. 2008;Jul(7):2152–2159. doi:10.1158/1535-7163.MCT-08-0021
   Web of Science ®Google Scholar
• Hu Q, Gong JP, Li J, Zhong SL, Tang J-H. Down-regulation of miRNA-452 is associated with adriamycin-resistance in breast cancer cells. Asian Pacific J Cancer Prev. 2014;15(13):5137–5142. doi:10.7314/APJCP.2014.15.13.5137
   PubMedGoogle Scholar
• Du F, Yu L, Wu Y, et al. miR-137 alleviates doxorubicin resistance in breast cancer through inhibition of epithelial-mesenchymal transition by targeting DUSP4. Cell Death Dis. 2019;10(12):922. doi:10.1038/s41419-019-2164-231801953
   PubMed Web of Science ®Google Scholar
• Hong T, Ding J, Li W. miR-7 reverses breast cancer resistance to chemotherapy by targeting MRP1 and BCL2. Onco Targets Ther. 2019;12:11097–11105. doi:10.2147/OTT.S21378031908478
   PubMed Web of Science ®Google Scholar
• Patel N, Garikapati KR, Pandita RK, et al. miR-15a/miR-16 down-regulates BMI1, impacting Ub-H2A mediated DNA repair and breast cancer cell sensitivity to doxorubicin. Sci Rep. 2017;7(1):4263. doi:10.1038/s41598-017-02800-228655885
   PubMed Web of Science ®Google Scholar
• Wang H, Liu K, Chi Z, et al. Interplay of MKP-1 and Nrf2 drives tumor growth and drug resistance in non-small cell lung cancer. Aging. 2019;11(23):11329–11346. doi:10.18632/aging.10253131811110
   PubMedGoogle Scholar
• Yen CH, Hsiao HH. NRF2 is one of the players involved in bone marrow mediated drug resistance in multiple myeloma. Int J Mol Sci. 2018;19(11):3503. doi:10.3390/ijms19113503
   PubMed Web of Science ®Google Scholar